Sintilimab

Sintilimab (IBI308) is a safe and effectivel humanized IgG4 monoclonal antibody that binds to PD-1 with a KD value of 74 pM. Sintilimab blocks the interaction of PD-1 with its ligands (PD-L1 and PL-L2), consequently helping to restore the endogenous antitumour T-cell response. Sintilimab combined with prebiotics inhibits tumor volume and regulates immune cell subpopulation balance in lung adenocarcinoma mice. Sintilimab can be used for the research of classical Hodgkin's lymphoma, non-small cell lung cancer and oesophageal cancer[1][2][3][4][5].

Product Specifications

CAS Number

[2072873-06-2]

Product Name Alternative

IBI308

UNSPSC

12352203

Target

PD-1/PD-L1

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/sintilimab.html

Purity

99.1

Solubility

H2O

Smiles

[Sintilimab]

Molecular Weight

(144.04 kDa)

References & Citations

[1]Sheridan M Hoy. Sintilimab: First Global Approval Drugs. 2019 Feb;79 (3) :341-346.|[2]Wang J, et al Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit. MAbs. 2019 Nov-Dec;11 (8) :1443-1451.|[3]Zhang L, et al. Sintilimab: A Promising Anti-Tumor PD-1 Antibody. Front Oncol. 2020 Nov 26;10:594558.|[4]Yan Q, et al. Prebiotics Modulate Gut Microbiota-mediated T-cell Immunity to Enhance the Inhibitory Effect of Sintilimab in Lewis Lung Adenocarcinoma Model Mice. Anticancer Agents Med Chem. 2023;23 (17) :1966-1973.|[5]Zhang L, et al. Sintilimab for the treatment of non-small cell lung cancer. Biomark Res. 2022 Apr 18;10 (1) :23.|[6]Lou B, et al. Preclinical Characterization of GLS-010 (Zimberelimab), a Novel Fully Human Anti-PD-1 Therapeutic Monoclonal Antibody for Cancer. Front Oncol. 2021 Sep 15;11:736955.